New guidelines from two leading medical associations suggest that efforts to reduce bad cholesterol should focus on ...

Cardiovascular disease is about to become the most expensive problem in American medicine. The American Heart Association fired a warning shot in late April: U.S. heart disease costs are on pace to ...

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of ...

Decisions on regulatory approval from EMA, UK, and Switzerland for obicetrapib and obicetrapib/ezetimibe fixed-dose combination expected in 2H26, and based on the outcomes, with potential launches by ...

She has high LDL cholesterol. Does she really need a statin? This case challenges the algorithm, exposes hidden trade-offs, ...

The NPPA has revised retail prices for 42 drug formulations, including anti-diabetic drugs and antibiotics, ensuring compliance with the Drugs Prices Control Order (DPCO).

New research suggests that pairing a moderate-intensity statin with ezetimibe can match the cardiovascular benefits of high-intensity statins while reducing the likelihood of developing type 2 ...

New Delhi [India], May 6 (ANI): The National Pharmaceutical Pricing Authority (NPPA) has revised the retail prices of 42 drug formulations under the Drugs Prices Control Order (DPCO), according to a ...

Wall Street remains bullish despite the losses. Analysts rate the stock a Strong Buy, with 14 of 15 analysts recommending purchase and just one rating it a hold. The consensus price target of $49.47 ...

If your doctor suggested you take a statin but you’re not following that advice, you’re not the only one who isn’t filling that prescription. Many people who are candidates for these popular ...

Atherosclerotic cardiovascular diseases are a leading global cause of death, driven significantly by elevated low‐density lipoprotein cholesterol levels. Despite the emergence of effective ...